Keala Miles

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023

Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.

Dexcom is relying on the interest and sales of its new continuous glucose monitor--which recently received FDA approval--to boost revenue (and stock value).

Revenue loss and a recent sell-off confirm that Cano Health stock may be struggling right now but a membership-focused strategy could help them recover.

How do Costco Wholesale and Amazon.com compare at the end of the year, and does this information affect their moderate buy ratings?

Discount retailers can be strong stock investments as their share price is often more appealing though they are not always reliable

Christmas time tends to be big for retailers, which can make them good bets for investors. Here are three moderate buy stocks as we approach year's end.

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

Okta is struggling but a recent earnings beat has boosted expectations. Can they maintain this momentum and get out of the red?

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

Salesforce, climbing out of a rough spot, still may not make the best short-term investment. In the future, it could make a big move.

Without the ability to turn significant profits, Alibaba is struggling. Fortunately, the industry as a whole is facing challenges, so watch the sector closely.

Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.

Penny stocks are cheap, but risky because they can shift quickly and in big ways. Here are two penny stocks making moves up and one heading down.

Vision Hydrogen Corporation decalred 2-for-1 split and changed their name to Vision Energy; Along with their green energy projects, this should entice investors

DraftKings share price continues to slip, even with a revenue beat and fewer losses than expected, and analysts have rated the stock a moderate Buy.

DoorDash has not done too well since its IPO but in a couple years, sales have improved greatly. Don't let sluggish earnings deter you from a potential buy.

Twilio's financials suggest uncertainty but analysts believe a rebound may be coming soon, as they give it a HOLD rating.

AMD is down but this could be the start of another rebound as sales and earnings show promise in the long term, particularly when compared against competitors.

Analysts believe Paypal could be a Strong Buy as earnings are not only steady but growing, even amid tough competition; thanks to resilient sales.

Apple could have better long-term promise than its peers and industry thanks to strong earnings and a new revenue strategy.

Shares of Nvidia Corp (NASDAQ: NVDA) slipped more than 6.8% on Wednesday, to a value of $169.38, during what turned out to be a rather inexorable day on the trading...